Utepreva LLC today announced the launch of the Utepreva Endometrial Sampler, a patented, FDA 510(k)-cleared, single-use endometrial sampling device engineered to enhance tissue capture and support ...

Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.

Earlier in April 2026, BioNTech reported positive primary Phase 2 results for its HER2‑targeted antibody-drug conjugate trastuzumab pamirtecan in previously treated, advanced endometrial cancer, ...

A phase 2 study suggests that immunotherapy plus radiation could spare some patients with advanced endometrial cancer from chemotherapy.

ACOG issued updated guidance recommending endometrial tissue sampling as well as transvaginal ultrasonography when initially ...

Women who have abnormal bleeding after menopause typically undergo a non-invasive procedure — a transvaginal ultrasound — to look for signs of uterine cancer. But research suggests that test misses ...

In this study, researchers aimed to identify endometrial cancer patient preferences and gather insights on how these preferences might inform treatment decisions.

“Endometrial cancer treatment generally has a high success rate, especially when the cancer is found early,” says John Wallbillich, MD, gynecologic oncologist at the Barbara Ann Karmanos Cancer ...

Recurrent/metastatic EC has a poor long-term prognosis, and treatment options are limited beyond first line, said Pothuri.